» Articles » PMID: 33181718

Sputum Characteristics and Airway Clearance Methods in Patients with Severe COVID-19

Overview
Specialty General Medicine
Date 2020 Nov 12
PMID 33181718
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Critically ill patients with coronavirus disease 2019 (COVID-19) have a high case fatality rate. Hence, controlling the disease progression of severely ill COVID-19 patients to avoid the development of severe-to-critical COVID-19 is the most important target of COVID-19 treatment. The latest autopsy results of COVID-19 patients have shown the presence of viscous secretions in the airways. However, no studies are available that specifically describe and analyze the sputum characteristics and the effects of various sputum drainage methods on the prognosis of COVID-19 patients. In our study, we found that elderly COVID-19 patients were more susceptible to progression to critical illness (P = .024) and were likely to have accompanying lymphopenia (P = .035) or increased neutrophil counts (P = .019). We observed that there was a higher proportion of patients with Grade 3 sticky sputum in the critically ill group than in the noncritically ill group (P = .026), suggesting that changes in sputum characteristics may be one of the early warning signs of critical COVID-19. In addition, we found that the application rates of large doses of ambroxol (P = .043) and prone-position drainage (P = .037) were relatively high in COVID-19 patients with good prognoses, suggesting that the early application of large doses of expectorant drugs and prone-position drainage in COVID-19 patients may avoid progression to critical illness and improve the prognosis.

Citing Articles

Impact of Nebulized BromAc on Mucus Plug Clearance in a Mechanically Ventilated Ex Vivo Ovine Lung Model of Obstructive Respiratory Conditions.

Valle N, Eapen M, Pillai K, Morris R, Akhter J, Mekkawy A Life (Basel). 2024; 14(9).

PMID: 39337895 PMC: 11433166. DOI: 10.3390/life14091111.


Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.

Urakov A, Urakova N, Reshetnikov A, Shklyaev A, Nikolenko V, Osipov A Curr Top Med Chem. 2024; 24(25):2191-2210.

PMID: 39253918 DOI: 10.2174/0115680266322046240819053909.


Nursing Practice of Airway Care Interventions and Prone Positioning in ICU Patients with COVID-19-A Dutch National Survey.

Esmeijer A, van der Ven F, Koornstra E, Kuipers L, van Oosten P, Swart P J Clin Med. 2024; 13(7).

PMID: 38610748 PMC: 11012421. DOI: 10.3390/jcm13071983.


Efficacy of respiratory rehabilitation in patients with COVID-19: a retrospective study.

Zhang Z, Wang C, Li Z, Liu Y, Nie Y, Zhang J BMC Pulm Med. 2024; 24(1):152.

PMID: 38532376 PMC: 10964677. DOI: 10.1186/s12890-024-02969-z.


One stone two birds: anti-inflammatory bronchodilators as a potential pharmacological strategy for COVID-19.

Yu Y, Fang B, Yang X, Zheng Y Front Pharmacol. 2023; 14:1185076.

PMID: 37214443 PMC: 10192734. DOI: 10.3389/fphar.2023.1185076.


References
1.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

2.
Liu Q, Wang R, Qu G, Wang Y, Liu P, Zhu Y . Gross examination report of a COVID-19 death autopsy. Fa Yi Xue Za Zhi. 2020; 36(1):21-23. DOI: 10.12116/j.issn.1004-5619.2020.01.005. View

3.
Cucinotta D, Vanelli M . WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020; 91(1):157-160. PMC: 7569573. DOI: 10.23750/abm.v91i1.9397. View

4.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

5.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View